loading
前日終値:
$2.99
開ける:
$3.02
24時間の取引高:
297.79K
Relative Volume:
0.18
時価総額:
$165.59M
収益:
$2.81M
当期純損益:
$-97.34M
株価収益率:
-1.6869
EPS:
-1.8
ネットキャッシュフロー:
$-91.47M
1週間 パフォーマンス:
-8.28%
1か月 パフォーマンス:
-13.25%
6か月 パフォーマンス:
-60.14%
1年 パフォーマンス:
-30.64%
1日の値動き範囲:
Value
$2.955
$3.08
1週間の範囲:
Value
$2.86
$3.30
52週間の値動き範囲:
Value
$2.86
$13.70

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name
名前
Fulcrum Therapeutics Inc
Name
セクター
Healthcare (1195)
Name
電話
617-651-8851
Name
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
職員
89
Name
Twitter
@fulcrumtx
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
FULC's Discussions on Twitter

FULC を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
FULC 3.03 165.59M 2.81M -97.34M -91.47M -1.80
VRTX 450.44 115.43B 10.63B -479.80M -1.35B 13.33
REGN 749.43 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 589.59 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.53 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.84 24.89B 3.30B -501.07M 1.03B 11.54

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-05-04 ダウングレード Goldman Buy → Neutral
2023-03-10 ダウングレード Credit Suisse Outperform → Neutral
2023-03-10 ダウングレード H.C. Wainwright Buy → Neutral
2023-03-09 ダウングレード Stifel Buy → Hold
2023-02-28 ダウングレード Morgan Stanley Overweight → Equal-Weight
2023-02-24 ダウングレード BofA Securities Neutral → Underperform
2022-11-15 開始されました Goldman Buy
2022-03-08 開始されました Oppenheimer Outperform
2022-03-03 アップグレード BofA Securities Underperform → Neutral
2021-08-11 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-04-26 再開されました Credit Suisse Outperform
2021-03-22 開始されました Credit Suisse Outperform
2021-03-02 開始されました Stifel Buy
2020-10-16 開始されました Piper Sandler Overweight
2020-08-12 ダウングレード BofA Securities Neutral → Underperform
2020-08-12 繰り返されました H.C. Wainwright Buy
2020-08-12 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-06-19 ダウングレード BofA/Merrill Buy → Neutral
2020-06-17 開始されました BTIG Research Buy
2019-10-03 開始されました H.C. Wainwright Buy
2019-08-12 開始されました BofA/Merrill Buy
すべてを表示

Fulcrum Therapeutics Inc (FULC) 最新ニュース

pulisher
Nov 20, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Nov 20, 2024
pulisher
Nov 19, 2024

Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche - The Globe and Mail

Nov 19, 2024
pulisher
Nov 19, 2024

Fulcrum Therapeutics stock hits 52-week low at $2.87 By Investing.com - Investing.com Canada

Nov 19, 2024
pulisher
Nov 18, 2024

Research Analysts Issue Forecasts for FULC FY2024 Earnings - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

Simplify Asset Management Inc. Sells 323,518 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 15, 2024

Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023) - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 5c - StreetInsider.com

Nov 14, 2024
pulisher
Nov 14, 2024

Fulcrum Therapeutics (NASDAQ:FULC) Receives Neutral Rating from HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Expert Ratings For Fulcrum Therapeutics - Benzinga

Nov 14, 2024
pulisher
Nov 14, 2024

Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ... - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Fulcrum Therapeutics appoints new independent director - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024 - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

Fulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Fulcrum Therapeutics appoints new independent director By Investing.com - Investing.com UK

Nov 13, 2024
pulisher
Nov 12, 2024

Fulcrum Therapeutics, Inc. Announces Board Changes - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

Fulcrum Therapeutics (FULC) to Present at Stifel Healthcare Conference | Investor Update | FULC Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 07, 2024

Fulcrum Therapeutics (FULC) Scheduled to Post Earnings on Wednesday - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET - The Manila Times

Nov 06, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Fulcrum Therapeuti - GuruFocus.com

Nov 05, 2024
pulisher
Nov 02, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Nov 02, 2024
pulisher
Oct 31, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Update - MarketBeat

Oct 31, 2024
pulisher
Oct 26, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Hold" from Brokerages - MarketBeat

Oct 26, 2024
pulisher
Oct 25, 2024

Fulcrum Before Q3 Earnings: How Should Investors Play the Stock? - Yahoo Finance

Oct 25, 2024
pulisher
Oct 21, 2024

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow - Yahoo Finance

Oct 21, 2024
pulisher
Oct 14, 2024

Ratios in Focus: Analyzing Fulcrum Therapeutics Inc (FULC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 14, 2024
pulisher
Oct 12, 2024

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 12, 2024
pulisher
Oct 11, 2024

Zevra Stock Surges Close to 70% in 3 Months: Here's Why - MSN

Oct 11, 2024
pulisher
Oct 10, 2024

The FULC Stock Puzzle: Unraveling Fulcrum Therapeutics Inc’s Fluctuating Performance - The InvestChronicle

Oct 10, 2024
pulisher
Oct 10, 2024

Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - SETE News

Oct 10, 2024
pulisher
Oct 10, 2024

Further weakness as Fulcrum Therapeutics (NASDAQ:FULC) drops 12% this week, taking three-year losses to 88% - Simply Wall St

Oct 10, 2024
pulisher
Oct 09, 2024

Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Stock Traders Buy Large Volume of Call Options on Fulcrum Therapeutics (NASDAQ:FULC) - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet? - Zacks Investment Research

Oct 09, 2024
pulisher
Oct 08, 2024

Dimensional Fund Advisors LP Grows Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Oct 08, 2024
pulisher
Oct 07, 2024

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares - Yahoo Finance

Oct 07, 2024
pulisher
Oct 07, 2024

Fulcrum Therapeutics Inc (FULC) stock on the rise: An overview - US Post News

Oct 07, 2024
pulisher
Oct 05, 2024

Goldman Sachs Upgrades Fulcrum Therapeutics (FULC) - MSN

Oct 05, 2024
pulisher
Oct 04, 2024

Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround - MSN

Oct 04, 2024
pulisher
Oct 02, 2024

An analyst sees good growth prospects for Fulcrum Therapeutics Inc (FULC) - SETE News

Oct 02, 2024
pulisher
Oct 02, 2024

Daily Market Movement: Fulcrum Therapeutics Inc (FULC) Sees a 0.84 Increase, Closing at 3.60 - The Dwinnex

Oct 02, 2024
pulisher
Oct 02, 2024

Biotech layoff tracker: 13 biotechs cut over 1,400 jobs - The Business Journals

Oct 02, 2024
pulisher
Oct 01, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $9.33 Consensus PT from Analysts - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

Fulcrum Therapeutics' SWOT analysis: stock outlook shifts on trial results - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Are Fulcrum Therapeutics Inc (FULC) shares a good deal now? - US Post News

Sep 30, 2024
pulisher
Sep 30, 2024

FULC Stock on the Rise: A Promising Investment - The InvestChronicle

Sep 30, 2024
pulisher
Sep 30, 2024

Fulcrum Therapeutics' SWOT analysis: stock outlook shifts on trial results By Investing.com - Investing.com Australia

Sep 30, 2024
pulisher
Sep 29, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Up 41.4% in September - MarketBeat

Sep 29, 2024
pulisher
Sep 27, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out - AccessWire

Sep 27, 2024

Fulcrum Therapeutics Inc (FULC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):